MedTrace Logo

Novel Drugs After Allo-HSCT in Patients With Multiple Myeloma

NCT04506320 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 202

Last updated 2023-10-05

No results posted yet for this study

Summary

This is a retrospective observational study of epidemiological surveillance, multicenter, non-profit, spontaneous, Italian on patients submitted to allo-HSCT among Italian Transplant Centers GITMO.

This study will evaluate all consecutive adult patients who received novel drugs after hematopoietic stem cell transplantation from related and unrelated donors between January 1, 2009 to December 31, 2018 in GITMO-affiliated Centers.

This study will evaluate approximately 300 subjects (with competitive enrolment) from GITMO investigational centers.

Conditions

Sponsors & Collaborators

  • Azienda Ospedaliero-Universitaria Careggi

    collaborator OTHER

  • Gruppo Italiano Trapianto di Midollo Osseo

    lead OTHER

Principal Investigators

  • Chiara Nozzoli · Azienda Ospedaliero-Universitaria Careggi

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-17
Primary Completion
2023-01-31
Completion
2023-01-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04506320 on ClinicalTrials.gov